Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.39 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.35 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.35 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.33 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.33 |
| ▸ | CMKLR1 | Q99788 | 1/20 | 0.33 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL652334 | 0.92 | AGTR1 (0.37) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL648072 | 0.92 | AGTR1 (0.39) | AGTR1DRD2TBXA2RLTB4R2 | |
| SCHEMBL652332 | 0.89 | AGTR1 (0.36) | AGTR1DRD2TBXA2RAGTR2CMKLR1 | |
| SCHEMBL648302 | 0.89 | AGTR1 (0.38) | AGTR1DRD2TBXA2RAGTR2CMKLR1 | |
| SCHEMBL649495 | 0.89 | TLR8 (0.36) | AGTR1DRD2TBXA2RAGTR2CMKLR1 | |
| SCHEMBL652771 | 0.88 | TLR8 (0.36) | AGTR1DRD2TBXA2RAGTR2CMKLR1 | |
| SCHEMBL650281 | 0.88 | AGTR1 (0.40) | AGTR1AGTR2LTB4R2 | |
| SCHEMBL651300 | 0.87 | AGTR1 (0.35) | AGTR1DRD2TBXA2RCMKLR1LTB4R2 | |
| SCHEMBL650986 | 0.87 | AGTR1 (0.35) | AGTR1DRD2TBXA2RCMKLR1LTB4R2 | |
| SCHEMBL648274 | 0.87 | AGTR1 (0.35) | AGTR1DRD2TBXA2RCMKLR1LTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 490 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117720674-B | Modified chitosan, preparation method thereof, retarding water reducer and application | 科之杰新材料集团有限公司 | 2026-05-19 | — | — | CN | claimed |
| CN-122010900-A | Organic ionic liquid formed by mixing double medicaments and application thereof | 苏州大学 | 2026-05-12 | — | — | CN | claimed |
| US-20260027074-A1 | ANIMAL THERAPEUTIC COMPOSITION AND ASSOCIATED METHODS | KODISCOVERY LLC (US) | 2026-01-29 | — | — | US | claimed |
| US-20260014106-A1 | COMBINATION IMMUNORESPONSE REGULATOR/IMMUNOTHERAPY SYSTEM AND METHOD | KODISCOVERY LLC (US) | 2026-01-15 | — | — | US | claimed |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | UCL BUSINESS LTD (GB) | 2025-01-16 | — | — | US | claimed |
| WO-2024255217-A1 | MODIFIED CHITOSAN AND PREPARATION METHOD THEREFOR, AND RETARDATION-TYPE WATER-REDUCING AGENT AND USE THEREOF | 科之杰新材料集团有限公司 | 2024-12-19 | — | — | WO | claimed |
| US-20240316012-A1 | METHODS FOR TREATING LYMPHOMA | NORTHWESTERN UNIVERSITY (US) | 2024-09-26 | — | — | US | claimed |
| WO-2024148139-A2 | METABOLITE-BASED PARTICLES AND COMPOSITIONS THEREOF FOR PREVENTING AND TREATING NEUROLOGICAL DISEASES AND DISORDERS | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) | 2024-07-11 | — | — | WO | claimed |
| CN-114605475-B | Oral Pt (IV) anticancer prodrugs containing 3-bromopyruvate ligand axially | 云南贵金属实验室有限公司 | 2024-02-02 | — | — | CN | claimed |
| CN-115386097-B | Hafnium-based metal organic framework material, preparation method thereof and contrast imaging application | 上海市第六人民医院 | 2024-01-26 | — | — | CN | claimed |
| US-20190127691-A1 | Metabolic Pressure for Stem Cell Differentiation and Purification | CHARLES STARK DRAPER LABORATORY INC (US) | 2019-05-02 | — | — | US | claimed |
| US-20180027802-A1 | Composition and use of substances for the in vitro stabilization of glucose, lactate and homocysteine in blood | WESER-BISSE PETRA (DE) | 2018-02-01 | — | — | US | claimed |
| EP-2883056-B1 | COMPOSITION AND USE OF SUBSTANCES FOR THE IN VITRO STABILIZATION OF GLUCOSE, LACTATE AND HOMOCYSTEINE IN BLOOD | WESER-BISSÉ PETRA (DE) | 2017-10-18 | — | — | EP | claimed |
| US-9788538-B2 | Method for the in vitro stabilization of glucose, lactate and homocysteine in a blood sample and method for determining the amount of blood components in a blood sample | Weser-Bisse, Petra (DE) | 2017-10-17 | — | — | US | claimed |
| US-20150208644-A1 | COMPOSITION AND USE OF SUBSTANCES FOR THE IN VITRO STABILIZATION OF GLUCOSE, LACTATE AND HOMOCYSTEINE IN BLOOD | WESER-BISSE, PETRA (DE) | 2015-07-30 | — | — | US | claimed |
| EP-2883056-A1 | COMPOSITION AND USE OF SUBSTANCES FOR THE IN VITRO STABILIZATION OF GLUCOSE, LACTATE AND HOMOCYSTEINE IN BLOOD | Weser-Bissé, Petra (DE) | 2015-06-17 | — | — | EP | claimed |
| WO-2014023612-A1 | COMPOSITION AND USE OF SUBSTANCES FOR THE IN VITRO STABILIZATION OF GLUCOSE, LACTATE AND HOMOCYSTEINE IN BLOOD | WESER-BISSÉ, Petra (DE) | 2014-02-13 | — | — | WO | claimed |
| EP-2696204-A1 | Composition and use of substances for the in vitro stabilization of glucose, lactate and homocysteine in blood | Weser-Bissé, Petra (DE) | 2014-02-12 | — | — | EP | claimed |
| US-20050159387-A1 | In-vivo energy depleting strategies for killing drug-resistant cancer cells | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2005-07-21 | — | — | US | claimed |
| WO-2003105862-A1 | IN-VIVO ENERGY DEPLETING STRATEGIES FOR KILLING DRUG-RESISTANT CANCER CELLS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2003-12-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014106-A1 | COMBINATION IMMUNORESPONSE REGULATOR/IMMUNOTHERAPY SYSTEM AND METHOD | FBP1, BPGM, TLR6 | AGTR1 3978/4885PDK1 166/4885PDK2 264/4885 |
| US-20250017950-A1 | COMPOUNDS FOR TREATING MITOCHONDRIAL DNA DISORDERS | POLRMT, TK2, GOT2 | AGTR1 4374/4885PDK1 212/4885PDK2 158/4885 |
| US-20260027074-A1 | ANIMAL THERAPEUTIC COMPOSITION AND ASSOCIATED METHODS | DERA, BPGM, FBP1 | AGTR1 3600/4885PDK1 80/4885PDK2 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.